XML 106 R46.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Notes to the consolidated financial statements - Additional Information (Details) € in Thousands, $ in Millions | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Jul. 31, 2020 EUR (€) item | Aug. 31, 2014 EUR (€) | Dec. 31, 2023 EUR (€) item | Dec. 31, 2022 EUR (€) item | Dec. 31, 2021 EUR (€) | Apr. 30, 2021 EUR (€) | Dec. 31, 2019 USD ($) | Nov. 30, 2017 USD ($)
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | € 53,758 | € 67,420 | € 102,990 |  |  |
Proceeds from issuing shares |  |  | € 235,840 |  | 404,062 |  |  |
Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding | item |  |  | 2 | 2 |  |  |  |
Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets | item |  |  | 2 | 1 |  |  |  |
Research And Development Services Combined With Ip License Member |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | € 31,051 | € 44,787 | 79,827 |  |  |
Product |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | 11,395 | 19,571 | 22,706 |  |  |
Research and development services |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | 11,312 | 3,062 | 457 |  |  |
Boehringer Ingelheim |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | 0 | 0 | 26,003 |  |  |
Upfront Payments Received Or Receivable |  | € 30,000 |  |  |  |  |  |
Option Fee payment |  | 5,000 |  |  |  |  |  |
Additional development milestone payments |  | € 7,000 |  |  |  |  |  |
Upfront Payment Revenue Recognized From Termination Of Agreement |  |  | 14,003 |  |  |  |  |
Ifrs Option Fee Payment Included In Contract Liabilities |  |  | 5,000 |  |  |  |  |
Development milestone payment included in contract liabilities |  |  | 7,000 |  |  |  |  |
CRISPR Therapeutics |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | 5,425 | 3,370 | 919 |  |  |
Upfront Payments Received Or Receivable | $ |  |  |  |  |  |  |  | $ 3
Genmab | Collaboration and License Agreement |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | 1,197 | 1,787 | 1,770 |  |  |
Upfront Payments Received Or Receivable | $ |  |  |  |  |  |  | $ 10 |
Equity investment | $ |  |  |  |  |  |  | $ 20 |
GSK [Member] | Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | 27,740 | 41,379 |  |  |  |
GSK [Member] | GlaxoSmithKline COVID Agreement |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | 10,530 | 20,884 |  |  |  |
Upfront Payments Received Or Receivable |  |  |  |  |  | € 75,000 |  |
GSK [Member] |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Proceeds from issuing shares | € 150,000 |  |  |  |  |  |  |
Upfront Payments Received Or Receivable | 120,000 |  | 220,000 |  |  |  |  |
Amount Eligible To Receive As One Time Reimbursable Payment For Manufacturing Capacity Reservation | 30,000 |  |  |  |  |  |  |
Amount Eligible To Receive As Development And Regulatory Milestone Payments | 320,000 |  |  |  |  |  |  |
Amount Eligible To Receive As Commercial Milestone Payments | € 380,000 |  |  |  |  |  |  |
Number of performance obligations | item | 2 |  |  |  |  |  |  |
GSK [Member] | Belgium |  |  |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |  |  |
Revenue recognized |  |  | € 47,128 | € 62,263 | € 74,298 |  |  |

X
- Definition The amount of additional development milestone payment received. + References No definition available. + Details
Name: | cvac_AdditionalDevelopmentMilestonePaymentsReceived
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount eligible to receive commercial milestone payments. + References No definition available. + Details
Name: | cvac_AmountEligibleToReceiveAsCommercialMilestonePayments
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount eligible to receive development and regulatory milestone payments. + References No definition available. + Details
Name: | cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount eligible to receive as a one-time reimbursable payment for manufacturing capacity reservation upon completion. + References No definition available. + Details
Name: | cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of development milestone payment included in contract liabilities + References No definition available. + Details
Name: | cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of Option fee payment included in contract liabilities + References No definition available. + Details
Name: | cvac_IfrsOptionFeePaymentIncludedInContractLiabilities
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding of the company. + References No definition available. + Details
Name: | cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding
Namespace Prefix: | cvac_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets. + References No definition available. + Details
Name: | cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets
Namespace Prefix: | cvac_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of performance obligations. + References No definition available. + Details
Name: | cvac_NumberOfPerformanceObligations
Namespace Prefix: | cvac_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of Option fee Payment received. + References No definition available. + Details
Name: | cvac_OptionFeePayment
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of upfront payment revenue recognized from termination of agreement. + References No definition available. + Details
Name: | cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of upfront payments received or receivable by the company. + References No definition available. + Details
Name: | cvac_UpfrontPaymentsReceivedOrReceivable
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 24 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph B16 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 54 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash inflow from issuing shares. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2023-01-01 -Paragraph 17 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProceedsFromIssuingShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cvac_BoehringerIngelheimMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cvac_CrisprTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cvac_GenmabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | cvac_IfrsTypeOfArrangementAxis=cvac_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | cvac_IfrsTypeOfArrangementAxis=cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | cvac_IfrsTypeOfArrangementAxis=cvac_GlaxosmithklineCovidAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_BE
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |